Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mocetinostat in CREBBP/EP300 Mutated Lymphoma
NCT02282358Phase 2Terminated
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Oct 2014
- Primary completion
- May 2023
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mocetinostat in diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Overall Response at 1 year. Started Oct 2014; status: terminated.
02
Drugs
mocetinostat
03
Conditions
diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT02282358.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02282358.